{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:58:58Z","timestamp":1774364338985,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2011,6,20]],"date-time":"2011-06-20T00:00:00Z","timestamp":1308528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Hypertension"],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:p>J Clin Hypertens (Greenwich). 2011;13:467\u2013472. \u00a92011 Wiley Periodicals, Inc.<\/jats:p><jats:p>Azilsartan medoxomil (AZL\u2010M) is a unique angiotensin II receptor blocker (ARB) under development for the treatment of hypertension. To compare this ARB with another in the class, the authors studied the effects of AZL\u2010M and valsartan (VAL) in 984 patients with primary hypertension in a randomized, double\u2010blind, multicenter study using ambulatory and clinic blood pressure (BP) measurements. The primary end point was change from baseline in 24\u2010hour mean ambulatory systolic BP following 24\u2003weeks of treatment. Hierarchical analysis testing for noninferiority was followed by superiority testing of AZL\u2010M (80 mg then 40\u2003mg) vs VAL. The mean age of participants was 58 years, 52% were men, and 15% were black. Baseline 24\u2010hour mean systolic BP was similar (approximately 145.6\u2003mm\u2003Hg) in each group. AZL\u2010M 40 mg and 80\u2003mg lowered 24\u2010hour mean systolic BP (\u221214.9 mm Hg and \u221215.3\u2003mm\u2003Hg, respectively) more than VAL 320\u2003mg (\u221211.3\u2003mm\u2003Hg; <jats:italic>P<\/jats:italic>&lt;.001 for 40\u2010mg and 80\u2010mg comparisons vs VAL). Clinic systolic BP reductions were consistent with the ambulatory results (\u221214.9\u2003mm\u2003Hg for AZL\u2010M 40\u2003mg and \u221216.9\u2003mm\u2003Hg for AZL\u2010M 80\u2003mg vs \u221211.6\u2003mm\u2003Hg for VAL; <jats:italic>P<\/jats:italic>=.015 and <jats:italic>P<\/jats:italic>&lt;.001, respectively). The reductions in 24\u2010hour mean and clinic diastolic BPs were also greater with both doses of AZL\u2010M than with VAL (<jats:italic>P<\/jats:italic>\u2264.001 for all comparisons). Small, reversible changes in serum creatinine occurred more often with AZL\u2010M than with VAL; otherwise, safety and tolerability parameters were similar among the three groups. These data demonstrate that AZL\u2010M across the effective dose range had superior efficacy to VAL at its maximal recommended dose without any meaningful increase in adverse events. These findings suggest that AZL\u2010M could provide higher rates of hypertension control compared with other ARBs in the class.<\/jats:p>","DOI":"10.1111\/j.1751-7176.2011.00482.x","type":"journal-article","created":{"date-parts":[[2011,6,20]],"date-time":"2011-06-20T13:26:57Z","timestamp":1308576417000},"page":"467-472","source":"Crossref","is-referenced-by-count":86,"title":["Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring"],"prefix":"10.1111","volume":"13","author":[{"given":"Domenic","family":"Sica","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William B.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Handley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Kupfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,6,20]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32834000be"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04311-6"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.19.2560"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.183885"},{"issue":"4","key":"e_1_2_7_6_2","first-page":"CD003822","article-title":"Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension","author":"Heran BS","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b1665"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80072-2"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08089-3"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16456-8"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010713"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011161"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011303"},{"key":"e_1_2_7_14_2","volume-title":"Global Investigator\u2019s Brochure: TAK\u2010491 Azilsartan Medoxomil","year":"2009"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000170138.56903.7a"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868090-00003"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001205"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000925"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(97)00491-3"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126097-200306000-00004"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.176636"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2010.00425.x"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.163402"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc4101.096153"}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1751-7176.2011.00482.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1751-7176.2011.00482.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T02:10:10Z","timestamp":1697335810000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1751-7176.2011.00482.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,20]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1111\/j.1751-7176.2011.00482.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1751-7176.2011.00482.x","archive":["Portico"],"relation":{},"ISSN":["1524-6175","1751-7176"],"issn-type":[{"value":"1524-6175","type":"print"},{"value":"1751-7176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,20]]}}}